Evaluating the antifibrotic potency of galunisertib in a human ex vivo model of liver fibrosis.

Theerut LuangmonkongSu SurigugaEmilia BigaevaMiriam BoersemaDorenda OosterhuisKoert P de JongDetlef SchuppanHenricus A M MutsaersPeter Olinga

Published in: British journal of pharmacology (2017)

Galunisertib is a drug that deserves to be further investigated for the treatment of liver fibrosis. Inhibition of SMAD2 phosphorylation is probably a central mechanism of action. In addition, blocking the production and maturation of collagens and promoting their degradation are related to the antifibrotic action of galunisertib.

Keyphrases

liver fibrosis
endothelial cells
epithelial mesenchymal transition
pulmonary fibrosis
transforming growth factor
induced pluripotent stem cells
emergency department
atomic force microscopy
signaling pathway
mass spectrometry